Global Human DNA Vaccines Market research

Human DNA Vaccines Comprehensive Study by Type (Human DNA vaccines, Animal DNA vaccines), Application (Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others}, Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)}), End Users (Human health, Animal health, Research application) Players and Region - Global Market Outlook to 2030

Human DNA Vaccines Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 30%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Human DNA vaccines are third generation vaccines meant to produce immune response against disease. The increasing risk of infectious diseases and rising number of antibiotics resistant demands cost effective vaccination solutions. The benefits of human DNA over conventional one are low risk of infection and stability at room temperature.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledInovio Pharmaceuticals [United States], GeneOne Life Science [South Korea], MedImmune [United States], Immunomic Therapeutics [United States], Astellas Pharma [Japan], Pharos Biologicals [United States], Sanofi [France], Hoffmann-La Roche [Switzerland], CureVac [Germany] and Boehringer Ingelheim [Germany]


According to AMA, the market for Human DNA Vaccines is expected to register a CAGR of 30.0% during the forecast period to 2030. This growth is primarily driven by Growing Prevalence of Infectious Disease and High Effectiveness of Human DNA Vaccines Compare to Conventional Medicines.

Globally, a noticeable market trend is evident Rising Demand for Low Cost and Effective Medicines The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Inovio Pharmaceuticals [United States], GeneOne Life Science [South Korea], MedImmune [United States], Immunomic Therapeutics [United States], Astellas Pharma [Japan], Pharos Biologicals [United States], Sanofi [France], Hoffmann-La Roche [Switzerland], CureVac [Germany] and Boehringer Ingelheim [Germany], etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The key manufacturers are targeting the innovations of the products with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions to maintain their presence in the market

Key Developments in the Market:
In January 2024, GSK and Elegen have teamed up to develop DNA-based medicines and vaccines, leveraging Elegen’s cell-free synthetic DNA production technology.
In February 2022, Alvea launched scalable, shelf-stable DNA vaccine development against new SARS-CoV-2 variants, with their breakthrough DNA vaccine, Alveavax, entering pre-clinical testing.

Influencing Trend:
Rising Demand for Low Cost and Effective Medicines and Customized Medicine Application and DNA Identification as a Therapy

Market Growth Drivers:
Growing Prevalence of Infectious Disease and High Effectiveness of Human DNA Vaccines Compare to Conventional Medicines

Challenges:
Chances of Contamination and Counterfeit Products and Problem of Products Recall

Restraints:
High Cost of Vaccine Developments

Opportunities:
Growing Focus and Investment in R&D of Vaccine and High Growth Prospect Emerging Economies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Human DNA Vaccines Market
- Analysis about New Entrants in Human DNA Vaccines Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Human DNA Vaccines Study Sheds Light on
— The Human DNA Vaccines Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Human DNA Vaccines industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Human DNA Vaccines industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Human DNA vaccines
  • Animal DNA vaccines
By Application
  • Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others}
  • Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)}
By End Users
  • Human health
  • Animal health
  • Research application

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Infectious Disease
      • 3.2.2. High Effectiveness of Human DNA Vaccines Compare to Conventional Medicines
    • 3.3. Market Challenges
      • 3.3.1. Chances of Contamination and Counterfeit Products
      • 3.3.2. Problem of Products Recall
    • 3.4. Market Trends
      • 3.4.1. Rising Demand for Low Cost and Effective Medicines
      • 3.4.2. Customized Medicine Application and DNA Identification as a Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human DNA Vaccines, by Type, Application, End Users and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human DNA Vaccines (Value)
      • 5.2.1. Global Human DNA Vaccines by: Type (Value)
        • 5.2.1.1. Human DNA vaccines
        • 5.2.1.2. Animal DNA vaccines
      • 5.2.2. Global Human DNA Vaccines by: Application (Value)
        • 5.2.2.1. Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others}
        • 5.2.2.2. Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)}
      • 5.2.3. Global Human DNA Vaccines by: End Users (Value)
        • 5.2.3.1. Human health
        • 5.2.3.2. Animal health
        • 5.2.3.3. Research application
      • 5.2.4. Global Human DNA Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Human DNA Vaccines (Volume)
      • 5.3.1. Global Human DNA Vaccines by: Type (Volume)
        • 5.3.1.1. Human DNA vaccines
        • 5.3.1.2. Animal DNA vaccines
      • 5.3.2. Global Human DNA Vaccines by: Application (Volume)
        • 5.3.2.1. Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others}
        • 5.3.2.2. Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)}
      • 5.3.3. Global Human DNA Vaccines by: End Users (Volume)
        • 5.3.3.1. Human health
        • 5.3.3.2. Animal health
        • 5.3.3.3. Research application
      • 5.3.4. Global Human DNA Vaccines Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Human DNA Vaccines (Price)
      • 5.4.1. Global Human DNA Vaccines by: Type (Price)
  • 6. Human DNA Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Inovio Pharmaceuticals [United States]
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GeneOne Life Science [South Korea]
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. MedImmune [United States]
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Immunomic Therapeutics [United States]
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma [Japan]
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pharos Biologicals [United States]
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi [France]
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hoffmann-La Roche [Switzerland]
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CureVac [Germany]
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boehringer Ingelheim [Germany]
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Human DNA Vaccines Sale, by Type, Application, End Users and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human DNA Vaccines (Value)
      • 7.2.1. Global Human DNA Vaccines by: Type (Value)
        • 7.2.1.1. Human DNA vaccines
        • 7.2.1.2. Animal DNA vaccines
      • 7.2.2. Global Human DNA Vaccines by: Application (Value)
        • 7.2.2.1. Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others}
        • 7.2.2.2. Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)}
      • 7.2.3. Global Human DNA Vaccines by: End Users (Value)
        • 7.2.3.1. Human health
        • 7.2.3.2. Animal health
        • 7.2.3.3. Research application
      • 7.2.4. Global Human DNA Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Human DNA Vaccines (Volume)
      • 7.3.1. Global Human DNA Vaccines by: Type (Volume)
        • 7.3.1.1. Human DNA vaccines
        • 7.3.1.2. Animal DNA vaccines
      • 7.3.2. Global Human DNA Vaccines by: Application (Volume)
        • 7.3.2.1. Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others}
        • 7.3.2.2. Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)}
      • 7.3.3. Global Human DNA Vaccines by: End Users (Volume)
        • 7.3.3.1. Human health
        • 7.3.3.2. Animal health
        • 7.3.3.3. Research application
      • 7.3.4. Global Human DNA Vaccines Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Human DNA Vaccines (Price)
      • 7.4.1. Global Human DNA Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human DNA Vaccines: by Type(USD Million)
  • Table 2. Human DNA Vaccines Human DNA vaccines , by Region USD Million (2018-2023)
  • Table 3. Human DNA Vaccines Animal DNA vaccines , by Region USD Million (2018-2023)
  • Table 4. Human DNA Vaccines: by Application(USD Million)
  • Table 5. Human DNA Vaccines Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others} , by Region USD Million (2018-2023)
  • Table 6. Human DNA Vaccines Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)} , by Region USD Million (2018-2023)
  • Table 7. Human DNA Vaccines: by End Users(USD Million)
  • Table 8. Human DNA Vaccines Human health , by Region USD Million (2018-2023)
  • Table 9. Human DNA Vaccines Animal health , by Region USD Million (2018-2023)
  • Table 10. Human DNA Vaccines Research application , by Region USD Million (2018-2023)
  • Table 11. South America Human DNA Vaccines, by Country USD Million (2018-2023)
  • Table 12. South America Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 13. South America Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 14. South America Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 15. Brazil Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 16. Brazil Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 17. Brazil Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 18. Argentina Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 19. Argentina Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 20. Argentina Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 21. Rest of South America Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 24. Asia Pacific Human DNA Vaccines, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 28. China Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 29. China Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 30. China Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 31. Japan Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 32. Japan Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 33. Japan Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 34. India Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 35. India Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 36. India Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 37. South Korea Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 38. South Korea Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 39. South Korea Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 40. Taiwan Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 41. Taiwan Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 42. Taiwan Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 43. Australia Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 44. Australia Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 45. Australia Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 49. Europe Human DNA Vaccines, by Country USD Million (2018-2023)
  • Table 50. Europe Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 51. Europe Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 52. Europe Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 53. Germany Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 54. Germany Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 55. Germany Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 56. France Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 57. France Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 58. France Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 59. Italy Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 60. Italy Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 61. Italy Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 62. United Kingdom Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 65. Netherlands Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 66. Netherlands Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 67. Netherlands Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 68. Rest of Europe Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 71. MEA Human DNA Vaccines, by Country USD Million (2018-2023)
  • Table 72. MEA Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 73. MEA Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 74. MEA Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 75. Middle East Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 76. Middle East Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 77. Middle East Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 78. Africa Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 79. Africa Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 80. Africa Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 81. North America Human DNA Vaccines, by Country USD Million (2018-2023)
  • Table 82. North America Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 83. North America Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 84. North America Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 85. United States Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 86. United States Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 87. United States Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 88. Canada Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 89. Canada Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 90. Canada Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 91. Mexico Human DNA Vaccines, by Type USD Million (2018-2023)
  • Table 92. Mexico Human DNA Vaccines, by Application USD Million (2018-2023)
  • Table 93. Mexico Human DNA Vaccines, by End Users USD Million (2018-2023)
  • Table 94. Human DNA Vaccines Sales: by Type(K Tons)
  • Table 95. Human DNA Vaccines Sales Human DNA vaccines , by Region K Tons (2018-2023)
  • Table 96. Human DNA Vaccines Sales Animal DNA vaccines , by Region K Tons (2018-2023)
  • Table 97. Human DNA Vaccines Sales: by Application(K Tons)
  • Table 98. Human DNA Vaccines Sales Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others} , by Region K Tons (2018-2023)
  • Table 99. Human DNA Vaccines Sales Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)} , by Region K Tons (2018-2023)
  • Table 100. Human DNA Vaccines Sales: by End Users(K Tons)
  • Table 101. Human DNA Vaccines Sales Human health , by Region K Tons (2018-2023)
  • Table 102. Human DNA Vaccines Sales Animal health , by Region K Tons (2018-2023)
  • Table 103. Human DNA Vaccines Sales Research application , by Region K Tons (2018-2023)
  • Table 104. South America Human DNA Vaccines Sales, by Country K Tons (2018-2023)
  • Table 105. South America Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 106. South America Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 107. South America Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 108. Brazil Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 109. Brazil Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 110. Brazil Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 111. Argentina Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 112. Argentina Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 113. Argentina Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 114. Rest of South America Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 115. Rest of South America Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 116. Rest of South America Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 117. Asia Pacific Human DNA Vaccines Sales, by Country K Tons (2018-2023)
  • Table 118. Asia Pacific Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 119. Asia Pacific Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 120. Asia Pacific Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 121. China Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 122. China Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 123. China Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 124. Japan Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 125. Japan Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 126. Japan Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 127. India Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 128. India Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 129. India Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 130. South Korea Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 131. South Korea Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 132. South Korea Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 133. Taiwan Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 134. Taiwan Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 135. Taiwan Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 136. Australia Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 137. Australia Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 138. Australia Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 139. Rest of Asia-Pacific Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 140. Rest of Asia-Pacific Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 141. Rest of Asia-Pacific Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 142. Europe Human DNA Vaccines Sales, by Country K Tons (2018-2023)
  • Table 143. Europe Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 144. Europe Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 145. Europe Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 146. Germany Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 147. Germany Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 148. Germany Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 149. France Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 150. France Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 151. France Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 152. Italy Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 153. Italy Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 154. Italy Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 155. United Kingdom Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 156. United Kingdom Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 157. United Kingdom Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 158. Netherlands Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 159. Netherlands Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 160. Netherlands Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 161. Rest of Europe Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 162. Rest of Europe Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 163. Rest of Europe Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 164. MEA Human DNA Vaccines Sales, by Country K Tons (2018-2023)
  • Table 165. MEA Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 166. MEA Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 167. MEA Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 168. Middle East Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 169. Middle East Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 170. Middle East Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 171. Africa Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 172. Africa Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 173. Africa Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 174. North America Human DNA Vaccines Sales, by Country K Tons (2018-2023)
  • Table 175. North America Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 176. North America Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 177. North America Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 178. United States Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 179. United States Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 180. United States Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 181. Canada Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 182. Canada Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 183. Canada Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 184. Mexico Human DNA Vaccines Sales, by Type K Tons (2018-2023)
  • Table 185. Mexico Human DNA Vaccines Sales, by Application K Tons (2018-2023)
  • Table 186. Mexico Human DNA Vaccines Sales, by End Users K Tons (2018-2023)
  • Table 187. Human DNA Vaccines: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Human DNA Vaccines: by Type(USD Million)
  • Table 199. Human DNA Vaccines Human DNA vaccines , by Region USD Million (2025-2030)
  • Table 200. Human DNA Vaccines Animal DNA vaccines , by Region USD Million (2025-2030)
  • Table 201. Human DNA Vaccines: by Application(USD Million)
  • Table 202. Human DNA Vaccines Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others} , by Region USD Million (2025-2030)
  • Table 203. Human DNA Vaccines Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)} , by Region USD Million (2025-2030)
  • Table 204. Human DNA Vaccines: by End Users(USD Million)
  • Table 205. Human DNA Vaccines Human health , by Region USD Million (2025-2030)
  • Table 206. Human DNA Vaccines Animal health , by Region USD Million (2025-2030)
  • Table 207. Human DNA Vaccines Research application , by Region USD Million (2025-2030)
  • Table 208. South America Human DNA Vaccines, by Country USD Million (2025-2030)
  • Table 209. South America Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 210. South America Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 211. South America Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 212. Brazil Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 213. Brazil Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 214. Brazil Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 215. Argentina Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 216. Argentina Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 217. Argentina Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 218. Rest of South America Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 219. Rest of South America Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 220. Rest of South America Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 221. Asia Pacific Human DNA Vaccines, by Country USD Million (2025-2030)
  • Table 222. Asia Pacific Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 223. Asia Pacific Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 224. Asia Pacific Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 225. China Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 226. China Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 227. China Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 228. Japan Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 229. Japan Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 230. Japan Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 231. India Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 232. India Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 233. India Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 234. South Korea Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 235. South Korea Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 236. South Korea Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 237. Taiwan Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 238. Taiwan Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 239. Taiwan Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 240. Australia Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 241. Australia Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 242. Australia Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 243. Rest of Asia-Pacific Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 246. Europe Human DNA Vaccines, by Country USD Million (2025-2030)
  • Table 247. Europe Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 248. Europe Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 249. Europe Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 250. Germany Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 251. Germany Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 252. Germany Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 253. France Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 254. France Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 255. France Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 256. Italy Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 257. Italy Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 258. Italy Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 259. United Kingdom Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 260. United Kingdom Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 261. United Kingdom Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 262. Netherlands Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 263. Netherlands Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 264. Netherlands Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 265. Rest of Europe Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 266. Rest of Europe Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 267. Rest of Europe Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 268. MEA Human DNA Vaccines, by Country USD Million (2025-2030)
  • Table 269. MEA Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 270. MEA Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 271. MEA Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 272. Middle East Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 273. Middle East Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 274. Middle East Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 275. Africa Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 276. Africa Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 277. Africa Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 278. North America Human DNA Vaccines, by Country USD Million (2025-2030)
  • Table 279. North America Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 280. North America Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 281. North America Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 282. United States Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 283. United States Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 284. United States Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 285. Canada Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 286. Canada Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 287. Canada Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 288. Mexico Human DNA Vaccines, by Type USD Million (2025-2030)
  • Table 289. Mexico Human DNA Vaccines, by Application USD Million (2025-2030)
  • Table 290. Mexico Human DNA Vaccines, by End Users USD Million (2025-2030)
  • Table 291. Human DNA Vaccines Sales: by Type(K Tons)
  • Table 292. Human DNA Vaccines Sales Human DNA vaccines , by Region K Tons (2025-2030)
  • Table 293. Human DNA Vaccines Sales Animal DNA vaccines , by Region K Tons (2025-2030)
  • Table 294. Human DNA Vaccines Sales: by Application(K Tons)
  • Table 295. Human DNA Vaccines Sales Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung cancer, Melanoma and Other)}, {(Infectious disease-CMV, HBV, HCV, HIV, Influenza and Others)}, {Allergies and Others} , by Region K Tons (2025-2030)
  • Table 296. Human DNA Vaccines Sales Veterinary Diseases {(Canine melanoma, Leishmaniasis, Equine West Nile Virus and Others)} , by Region K Tons (2025-2030)
  • Table 297. Human DNA Vaccines Sales: by End Users(K Tons)
  • Table 298. Human DNA Vaccines Sales Human health , by Region K Tons (2025-2030)
  • Table 299. Human DNA Vaccines Sales Animal health , by Region K Tons (2025-2030)
  • Table 300. Human DNA Vaccines Sales Research application , by Region K Tons (2025-2030)
  • Table 301. South America Human DNA Vaccines Sales, by Country K Tons (2025-2030)
  • Table 302. South America Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 303. South America Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 304. South America Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 305. Brazil Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 306. Brazil Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 307. Brazil Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 308. Argentina Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 309. Argentina Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 310. Argentina Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 311. Rest of South America Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 312. Rest of South America Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 313. Rest of South America Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 314. Asia Pacific Human DNA Vaccines Sales, by Country K Tons (2025-2030)
  • Table 315. Asia Pacific Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 316. Asia Pacific Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 317. Asia Pacific Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 318. China Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 319. China Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 320. China Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 321. Japan Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 322. Japan Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 323. Japan Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 324. India Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 325. India Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 326. India Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 327. South Korea Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 328. South Korea Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 329. South Korea Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 330. Taiwan Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 331. Taiwan Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 332. Taiwan Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 333. Australia Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 334. Australia Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 335. Australia Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 336. Rest of Asia-Pacific Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 337. Rest of Asia-Pacific Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 338. Rest of Asia-Pacific Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 339. Europe Human DNA Vaccines Sales, by Country K Tons (2025-2030)
  • Table 340. Europe Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 341. Europe Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 342. Europe Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 343. Germany Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 344. Germany Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 345. Germany Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 346. France Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 347. France Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 348. France Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 349. Italy Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 350. Italy Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 351. Italy Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 352. United Kingdom Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 353. United Kingdom Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 354. United Kingdom Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 355. Netherlands Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 356. Netherlands Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 357. Netherlands Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 358. Rest of Europe Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 359. Rest of Europe Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 360. Rest of Europe Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 361. MEA Human DNA Vaccines Sales, by Country K Tons (2025-2030)
  • Table 362. MEA Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 363. MEA Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 364. MEA Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 365. Middle East Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 366. Middle East Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 367. Middle East Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 368. Africa Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 369. Africa Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 370. Africa Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 371. North America Human DNA Vaccines Sales, by Country K Tons (2025-2030)
  • Table 372. North America Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 373. North America Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 374. North America Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 375. United States Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 376. United States Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 377. United States Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 378. Canada Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 379. Canada Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 380. Canada Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 381. Mexico Human DNA Vaccines Sales, by Type K Tons (2025-2030)
  • Table 382. Mexico Human DNA Vaccines Sales, by Application K Tons (2025-2030)
  • Table 383. Mexico Human DNA Vaccines Sales, by End Users K Tons (2025-2030)
  • Table 384. Human DNA Vaccines: by Type(USD/Units)
  • Table 385. Research Programs/Design for This Report
  • Table 386. Key Data Information from Secondary Sources
  • Table 387. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human DNA Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Human DNA Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Human DNA Vaccines: by End Users USD Million (2018-2023)
  • Figure 7. South America Human DNA Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Human DNA Vaccines Share (%), by Country
  • Figure 9. Europe Human DNA Vaccines Share (%), by Country
  • Figure 10. MEA Human DNA Vaccines Share (%), by Country
  • Figure 11. North America Human DNA Vaccines Share (%), by Country
  • Figure 12. Global Human DNA Vaccines: by Type K Tons (2018-2023)
  • Figure 13. Global Human DNA Vaccines: by Application K Tons (2018-2023)
  • Figure 14. Global Human DNA Vaccines: by End Users K Tons (2018-2023)
  • Figure 15. South America Human DNA Vaccines Share (%), by Country
  • Figure 16. Asia Pacific Human DNA Vaccines Share (%), by Country
  • Figure 17. Europe Human DNA Vaccines Share (%), by Country
  • Figure 18. MEA Human DNA Vaccines Share (%), by Country
  • Figure 19. North America Human DNA Vaccines Share (%), by Country
  • Figure 20. Global Human DNA Vaccines: by Type USD/Units (2018-2023)
  • Figure 21. Global Human DNA Vaccines share by Players 2023 (%)
  • Figure 22. Global Human DNA Vaccines share by Players (Top 3) 2023(%)
  • Figure 23. Global Human DNA Vaccines share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Inovio Pharmaceuticals [United States] Revenue, Net Income and Gross profit
  • Figure 26. Inovio Pharmaceuticals [United States] Revenue: by Geography 2023
  • Figure 27. GeneOne Life Science [South Korea] Revenue, Net Income and Gross profit
  • Figure 28. GeneOne Life Science [South Korea] Revenue: by Geography 2023
  • Figure 29. MedImmune [United States] Revenue, Net Income and Gross profit
  • Figure 30. MedImmune [United States] Revenue: by Geography 2023
  • Figure 31. Immunomic Therapeutics [United States] Revenue, Net Income and Gross profit
  • Figure 32. Immunomic Therapeutics [United States] Revenue: by Geography 2023
  • Figure 33. Astellas Pharma [Japan] Revenue, Net Income and Gross profit
  • Figure 34. Astellas Pharma [Japan] Revenue: by Geography 2023
  • Figure 35. Pharos Biologicals [United States] Revenue, Net Income and Gross profit
  • Figure 36. Pharos Biologicals [United States] Revenue: by Geography 2023
  • Figure 37. Sanofi [France] Revenue, Net Income and Gross profit
  • Figure 38. Sanofi [France] Revenue: by Geography 2023
  • Figure 39. Hoffmann-La Roche [Switzerland] Revenue, Net Income and Gross profit
  • Figure 40. Hoffmann-La Roche [Switzerland] Revenue: by Geography 2023
  • Figure 41. CureVac [Germany] Revenue, Net Income and Gross profit
  • Figure 42. CureVac [Germany] Revenue: by Geography 2023
  • Figure 43. Boehringer Ingelheim [Germany] Revenue, Net Income and Gross profit
  • Figure 44. Boehringer Ingelheim [Germany] Revenue: by Geography 2023
  • Figure 45. Global Human DNA Vaccines: by Type USD Million (2025-2030)
  • Figure 46. Global Human DNA Vaccines: by Application USD Million (2025-2030)
  • Figure 47. Global Human DNA Vaccines: by End Users USD Million (2025-2030)
  • Figure 48. South America Human DNA Vaccines Share (%), by Country
  • Figure 49. Asia Pacific Human DNA Vaccines Share (%), by Country
  • Figure 50. Europe Human DNA Vaccines Share (%), by Country
  • Figure 51. MEA Human DNA Vaccines Share (%), by Country
  • Figure 52. North America Human DNA Vaccines Share (%), by Country
  • Figure 53. Global Human DNA Vaccines: by Type K Tons (2025-2030)
  • Figure 54. Global Human DNA Vaccines: by Application K Tons (2025-2030)
  • Figure 55. Global Human DNA Vaccines: by End Users K Tons (2025-2030)
  • Figure 56. South America Human DNA Vaccines Share (%), by Country
  • Figure 57. Asia Pacific Human DNA Vaccines Share (%), by Country
  • Figure 58. Europe Human DNA Vaccines Share (%), by Country
  • Figure 59. MEA Human DNA Vaccines Share (%), by Country
  • Figure 60. North America Human DNA Vaccines Share (%), by Country
  • Figure 61. Global Human DNA Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Inovio Pharmaceuticals [United States]
  • GeneOne Life Science [South Korea]
  • MedImmune [United States]
  • Immunomic Therapeutics [United States]
  • Astellas Pharma [Japan]
  • Pharos Biologicals [United States]
  • Sanofi [France]
  • Hoffmann-La Roche [Switzerland]
  • CureVac [Germany]
  • Boehringer Ingelheim [Germany]
Additional players considered in the study are as follows:
Merck & Co [United States] , Novartis Animal Health [Switzerland] , Vical [United States] , Astellas Pharma [Japan] , Dendreon [United States] , Afluria [Australia] , KINRIX [United Kingdom]
Select User Access Type

Key Highlights of Report


Mar 2024 207 Pages 70 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human DNA Vaccines Market research Quantitative research analysis
Global Human DNA Vaccines Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Human DNA Vaccines market are Inovio Pharmaceuticals [United States], GeneOne Life Science [South Korea], MedImmune [United States], Immunomic Therapeutics [United States], Astellas Pharma [Japan], Pharos Biologicals [United States], Sanofi [France], Hoffmann-La Roche [Switzerland], CureVac [Germany] and Boehringer Ingelheim [Germany], to name a few.
North America is dominating the Human DNA Vaccines Market.
"Chances of Contamination and Counterfeit Products " is seen as one of the major challenges by many Industry Players of Human DNA Vaccines Market
The Human DNA Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Human DNA Vaccines market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Human DNA Vaccines Market research Report?

Have a Query? Click Here

Other Related Reports

Thioctic Acid Comprehensive Study by Type (R-lipoic Acid, S-lipoic Acid), Application (Diabetes, Nerve Pain, Weight Loss, Skin Care, Others), Distribution Channel (Online (E-Commerce Stores), Offline...
$ 3650
Histidine Comprehensive Study by Type (Tablets, Capsules, Fluids, Others), Application (Food Industry, Pharmaceutical Industry, Biotechnology, R&D Laboratories, Medical Research Institutes, Others), ...
$ 3450
Animal Pharmaceutical Comprehensive Study by Type (Vaccines, Pharmaceuticals, Feed Additives, Diagnostics, Others), Application (Companion Animal, Poultry, Other), Disease (Orthopedic Diseases, Infec...
$ 3750
Creatine Kinase Comprehensive Study by Type (Kits & Reagents, Instruments), End-users (Hospitals, Clinics, Diagnostic Laboratories, Academic Research Institutes), Test Type (Colorimetric Assay Based ...
$ 3450
Methadone Comprehensive Study by Type (Oral Medicine (Tablets, Liquid), Injections), Application (Operation, Detoxification, Others) Players and Region - Global Market Outlook to 2026
$ 3500
Human Endostatin Comprehensive Study by Type (Idiopathic, Paraneoplastic), Application (Medical Care, Scientific Research, Others), Distribution Channel (Direct, Indirect) Players and Region - Global...
$ 3500